HOME >> BIOLOGY >> NEWS
UI researchers discover new activity in cystic fibrosis protein

Even well-studied proteins can reveal surprises. University of Iowa scientists have discovered a new enzyme activity for the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is the protein that is defective in cystic fibrosis, a common life-threatening genetic disease that affects primarily the lungs and pancreas of young people. The discovery, which appeared in the Dec. 26, 2003 issue of Cell, helps solve a long-standing puzzle about how this important protein works.

CFTR forms a channel, or pore, in the membrane of airway cells. When the channel is open, the salt chloride flows through it from one side of the membrane to the other. It has been known for many years that CFTR channel opening requires a molecule called ATP and that CFTR has an enzymatic activity called ATPase that uses ATP. ATP is the energy currency of the cell and the ATPase reaction spends the energy of ATP to power enzyme activity. Because chloride flows passively through the CFTR channel, it has long seemed puzzling that the opening of CFTR would require the substantial energy of ATP. Moreover, energy from ATP is not required to fuel any other ion channel.

The UI study now reveals that CFTR can function as an adenylate kinase enzyme. Like an ATPase, the adenylate kinase reaction uses ATP. But in contrast to an ATPase, an adenylate kinase enzyme also uses a related molecule called AMP. Importantly, the adenylate kinase neither consumes nor produces energy, but it controls channel opening. The study also suggests that in normal cells it is this enzyme activity rather than the ATPase that opens the CFTR channel.

"We think that in the normal physiologic context where AMP is present, CFTR would function as an adenylate kinase," said Christoph Randak, M.D., UI postdoctoral scholar in the UI Department of Internal Medicine and lead author of the study. "Thus, the CFTR channel may function without consuming a large amount of energy."

The UI study ma
'"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-335-9917
University of Iowa
27-Jan-2004


Page: 1 2

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. $7.5 Million grant to Yale researchers for role of viruses in cancer
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Joslin researchers clarify mechanisms for beta-cell formation
6. Virginia Tech researchers to release findings on Smith River Project
7. Molecular motor myosin VI moves hand over hand, researchers say
8. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
9. Emory researchers map structure of anti-cancer molecule
10. Leukemia stem cells identified by Stanford researchers
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...   Capricor Therapeutics, Inc. (NASDAQ: ... first-in-class biological therapies for cardiac and other medical ... terminate its license agreement with the Mayo Clinic ... "Our decision to return these rights ... efforts to advance our core cell and exosome-based ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
(Date:2/15/2017)... Inc. (Vanda) (NASDAQ: VNDA), today announced financial and ... year ended December 31, 2016. "2016 ... continued to demonstrate strong growth in our commercial ... Mihael H. Polymeropoulos, M.D., Vanda,s President and CEO. ... milestones underscores Vanda,s commitment to bringing important new ...
Breaking Biology Technology:
Cached News: